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Abstract
Objective To assess the effect of home based telehealth interventions
on the use of secondary healthcare and mortality.
Design Pragmatic, multisite, cluster randomised trial comparing
telehealth with usual care, using data from routine administrative
datasets. General practice was the unit of randomisation. We allocated
practices using a minimisation algorithm, and did analyses by intention
to treat.
Setting 179 general practices in three areas in England.
Participants 3230 people with diabetes, chronic obstructive pulmonary
disease, or heart failure recruited from practices between May 2008 and
November 2009.
Interventions Telehealth involved remote exchange of data between
patients and healthcare professionals as part of patients’ diagnosis and
management. Usual care reflected the range of services available in the
trial sites, excluding telehealth.
Main outcome measure Proportion of patients admitted to hospital
during 12 month trial period.
Results Patient characteristics were similar at baseline. Compared with
controls, the intervention group had a lower admission proportion within
12 month follow-up (odds ratio 0.82, 95% confidence interval 0.70 to
0.97, P=0.017). Mortality at 12 months was also lower for intervention
patients than for controls (4.6% v 8.3%; odds ratio 0.54, 0.39 to 0.75,
P<0.001). These differences in admissions and mortality remained
significant after adjustment. Themean number of emergency admissions
per head also differed between groups (crude rates, intervention 0.54 v
control 0.68); these changes were significant in unadjusted comparisons
(incidence rate ratio 0.81, 0.65 to 1.00, P=0.046) and after adjusting for
a predictive risk score, but not after adjusting for baseline characteristics.
Length of hospital stay was shorter for intervention patients than for
controls (mean bed days per head 4.87 v 5.68; geometric mean
difference −0.64 days, −1.14 to −0.10, P=0.023, which remained
significant after adjustment). Observed differences in other forms of
hospital use, including notional costs, were not significant in general.
Differences in emergency admissions were greatest at the beginning of
the trial, during which we observed a particularly large increase for the
control group.
Conclusions Telehealth is associated with lower mortality and
emergency admission rates. The reasons for the short term increases
in admissions for the control group are not clear, but the trial recruitment
processes could have had an effect.
Trial registration number International Standard RandomisedControlled
Trial Number Register ISRCTN43002091.
Introduction
Efforts worldwide are dealing with the increasing prevalence
of chronic disease among an ageing population. The past decade
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has seen the growing use of telehealth as one possible approach
to this problem. Telehealth involves the remote exchange of
data between a patient and healthcare professionals as part of
the patient’s diagnosis and healthcare management.1 2 Examples
include the monitoring of blood pressure and blood glucose.
Telehealth may help patients to better understand their health
conditions by providing tools for self monitoring, encourage
better self management of health problems, and alert
professional support if devices signal a problem. As a
consequence, telehealth promises better quality and more
appropriate care for each patient, as well as more efficient use
of healthcare resources by reducing the need for expensive
hospital care.
Some research suggests that telehealth can have a positive effect
on patients with chronic disease, such as improved patient
experiences, clinical indicators, and quality of life, and reduced
use of secondary healthcare (including emergency hospital
admissions).1 2 Yet, other studies have found either no effect or
a negative effect.3 4 Furthermore, such evidence is usually based
on assimilating findings from a number of small trials, which
could be difficult to generalise,3 and with many of these trials
not meeting robust evaluation standards.4 5 A recent review of
self monitoring of blood glucose for people with diabetes
concluded that there was a need for large controlled trials.6
Investment in telehealth has often been justified partly on the
basis that its cost can be recovered by reductions in the use of
secondary healthcare.7 However, assessing the scale of such an
effect is complicated. Simple study designs comparing stages
before and after an intervention can produce misleading results
by not having a control group to compare with, particularly if
the patients selected for intervention have a history of emergency
care. Such patients have a tendency to show reductions in use
of emergency care over time (that is, regression to the mean).8
Therefore, in the absence of a control group, whether observed
reductions are the effect of the intervention is unclear.
Analyses of hospital use are further complicated by the fact that
the distribution of admissions across patients can be highly
skewed. Some high risk patients account for a very high
proportion of admissions.9 Therefore, small differences in the
risk profile of patients receiving the intervention can greatly
affect observed outcomes in terms of hospital admission. Several
predictive risk models have been developed that use information
from a person’s health history to predict future hospital use,10 11
and can offer an opportunity for case mix adjustment. A further
limitation on the size of previous evaluation studies has been
the costs of obtaining information from patients, but it is now
possible to extract information from operational administrative
systems and use secure data linkage procedures to track resource
use.
In 2006, the Department of Health in England published a white
paper that included a focus on health and social care for people
with long term needs.12 The strategy proposed a series of
demonstrator pilots to drive whole systems redesign, supported
by advanced assistive technologies. These technologies included
telehealth, along with a system of remote, automatic, and passive
monitoring for patients with social care needs (known as
telecare). The result was the Whole System Demonstrator
project, funded by the Department of Health, which tested the
benefits of integrated care supported by telehealth and telecare
in three sites in England (Cornwall, Kent, and Newham).
One of the project’s aims was to test the effect of telehealth if
delivered at a larger scale than existing pilot schemes, which
were often limited to fewer than 100 patients. The resulting trial
was pragmatic in design, to recruit and randomise suitably large
numbers of patients and assess the effect of a broad class of
telehealth and telecare technologies in the context of routine
delivery of care provided by the United Kingdom’s health
service.7 8 The telehealth part of the study included people
diagnosed with chronic obstructive pulmonary disease, heart
failure, or diabetes. These conditions have high prevalence and
associated healthcare costs. The evaluation covered several
different dimensions.13 This article is one of five analyses, and
reports on how telehealth affected the use of secondary
healthcare and mortality. The other analyses will assess how
telehealth affected quality of life and cost effectiveness, and
explores the patient, professional, and organisation factors
related to implementation.
Methods
The trial protocol has been described by Bower and colleagues.13
Initial discussions with sites indicated that individual
randomisation of patients would probably not be acceptable to
stakeholders. Therefore, we used a pragmatic approach to
randomise general practices. Participants in practices allocated
to the control group were given usual care, which reflected the
range of services available in the trial sites, excluding telehealth,
and were offered telehealth or telecare at the end of the trial, if
they were still eligible at that point.
Choices of telehealth devices and monitoring systems varied
among the three trial sites, and there was no attempt to
standardise these technologies across sites. We included a broad
class of technologies, and the studywas not designed or powered
to examine differences between specific devices or monitoring
systems. Although sites used different protocols for allocating
peripheral devices, they all used a pulse oximeter for chronic
obstructive pulmonary disease, a glucometer for diabetes, and
weighing scales for heart failure. Sites asked participants to take
clinical readings at the same time each day for up to five days
per week, although the frequency was adjusted according to
their individual history. For example, a participant with diabetes
and well controlled blood glucose would be asked to take
readings less frequently than another participant with poorly
controlled blood glucose.
In addition to the telemonitoring aspect of the intervention,
symptom questions and educational messages were sent to
participants either via the telehealth base unit or via a set top
box connected to a television. At the end of each session, data
from clinical readings and symptom questions were transmitted
to monitoring centres via a secure server. Monitoring centres
were staffed by specialist nurses and community matrons from
local health organisations, who used protocols to respond to the
information from patients.
All practices in the geographical areas covered by three study
sites (Cornwall, Kent, and Newham in England) were eligible
to participate in the trial. Practices that accepted the invitation
to participate were allocated to an intervention or control group
via a centrally administered, minimisation algorithm that aimed
to ensure that the groups of practices were similar in terms of
practice size; deprivation index; proportion of non-white
patients; prevalence of diabetes, chronic obstructive pulmonary
disease, and heart failure; and site.Within each practice, patients
aged 18 years or over were deemed eligible on the basis of a
diagnosis in primary or secondary care of chronic obstructive
pulmonary disease, diabetes, or heart failure. We did not confer
eligibility on the basis of formal clinical assessment of disease
severity. Instead, patients were deemed eligible on the basis of
their inclusion on the relevant Quality Outcomes Framework
register in primary care; a confirmed medical diagnosis in
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primary or secondary care medical records, as indicated by
general practice Read codes or ICD-10 (international
classification of diseases, 10th revision) codes; or confirmation
of disease status by a local clinician (a general practitioner or
community matron) or the patient’s hospital consultant. We did
not exclude patients on the basis of additional physical
comorbidities.
To meet ethical obligations, sites asked patients to complete
and return a data sharing letter if they consented to their data
being shared with the research team. Once this letter had been
returned, patients received a “light touch” visit from members
of the site project team, sometimes including clinical staff. These
visits aimed to assess the suitability of the patient’s home for
telehealth, provide information regarding the trial, and provide
consent forms for participation. The study design required that
patients were blinded at the point of consent. However, owing
to the large sample size needed for the trial and the extended
period of recruitment, it was not possible to guarantee the
blinding of recruiters to the allocations of general practices
throughout the process.
We assessed the effect of telehealth at the patient level. The
primary endpoint was the proportion of people with an inpatient
admission to hospital within the 12month trial period. The study
was powered on the basis of detecting a relative change of 17.5%
from a baseline of 25% (from a priori site estimates), at 80%
power, and a two sided value of P<0.05. Previous studies in the
older population suggested that the intracluster correlation
coefficient would be about 0.001.14 We did sample size
calculations using the appropriate formulas,15 and found that
3000 patients would need to be recruited (25 patients from each
of 120 general practices). We examined mortality over 12
months and prespecified secondary endpoints (including the
number of inpatient bed days, emergency admissions, elective
admissions, outpatient attendances, and emergency department
visits, as well as the notional cost of hospital activity to
commissioners of care based on national tariff costs).
Participants were linked at the person level to data for inpatient
and outpatient secondary activity sourced fromHospital Episode
Statistics, a national data warehouse for England.16 Participants
were linked by the NHS Information Centre for health and social
care, a trusted third party that was the only organisation to have
access to both patient identifiers and data for secondary care
activity. A linked mortality file provided data for all deaths
occurring in and out of hospital. In addition, participants were
linked to local commissioning datasets on visits to emergency
departments, which included all visits to emergency department
and not just those that resulted in an admission, and to general
practice datasets. In these data, patient identifiable fields were
removed before transfer and NHS numbers encrypted.We used
this encrypted NHS number to link participants to the emergency
and general practice data.
We restricted analysis of inpatient activity to ordinary
admissions, and excluded transfers, regular ward attendances,
and maternity events (leaving patient classifications 1 and 2
only). Admissions were classified by defined admissionmethods
into emergency activity (codes 21-28) and elective activity (all
other codes excluding transfers). Bed days included stays after
emergency and elective admissions; same day admissions and
discharges were assigned a stay length of 1 bed day. We
restricted outpatient activity to appointments that were attended
(codes 5 and 6).
A separate paper is planned to detail the effect of telehealth on
costs. Here, we included notional costs of hospital care to
summarise overall levels of hospital use in the intervention and
treatment groups across the inpatient and outpatient categories.
We estimated notional costs of care, from Hospital Episode
Statistics data, by applying the set of mandatory and indicative
tariffs used in England for the reimbursement of inpatient and
outpatient care (2008-09 payment by results tariffs).17 These
tariffs assume a stay of a certain number of days (the “trim
point”), and allow hospitals to charge a prespecified amount for
each additional excess bed day. Costs were not adjusted for the
regional costs of providing care, and thus were effectively a
weighted activity measure that allowed robust comparison of
the magnitude of care received for control and intervention
participants. We did not include costs for activity not covered
by the tariffs, such as mental health, critical care, cystic fibrosis,
high cost drugs, and outpatient physiotherapy.
The current study was restricted to those patients linked to
administrative data who began the trial before 30 September
2009. The trial start date was taken as the date of telehealth
installation for intervention patients, and as the date of the “light
touch” visit for control patients. Analysis was based on
comparing activity over 12 months after this date, at the person
level.
Analysis of participants was on the basis of the intended
treatment allocations, and regardless of subsequent withdrawal
from the trial. For randomised trials, formal statistical tests on
the similarity of intervention and control patients have been
thought to be inappropriate, since allocations are known to have
been random.18However, in cluster randomised trials, selection
bias is theoretically possible, either through systematic
differences between practices in the control and intervention
groups, or because of similar differences at the individual level.19
We presented standardised differences as a summary measure
of differences between groups; we calculated a standardised
difference as the difference between the sample means (or
proportions), divided by the pooled standard deviation.20
Although various aspects of the trial design mitigated against
the risk of selection bias, differences between groups could still
have occurred by chance.We applied case mix adjustment using
three models to account for the effect of any differences between
groups (box).
In a cluster randomised trial, hospital use for individuals in the
same general practice will tend to be correlated. We accounted
for this degree of clustering by constructing multilevel models
that included random effects at the practice level. Logistic
regression was used for the admission proportion and mortality,
with the exponent of the coefficients used to calculate odds
ratios. For emergency admissions, elective admissions,
outpatient attendances, and emergency department visits, we
used Poisson regression and exponentiated the coefficients to
produce incidence rate ratios. Distribution of healthcare costs
and hospital bed days are typically skewed, with some very
large values and a considerable proportion of the population at
zero. Although opinions differ on how to analyse such data,21
we incremented and log transformed notional costs and bed
days to meet the assumptions needed for subsequent ordinary
least squares modelling. Model coefficients were exponentiated
to calculate geometric mean differences. We did all analyses in
Stata 11.22
The primary analysis assumed a 12 month follow-up for all
patients, regardless of whether they died or not. This tested for
differences between the groups in overall levels of hospital
activity after the introduction of telehealth. However, clinicians
and other healthcare professionals might also be interested in
how telehealth would affect patients’ experiences of admission
to hospital, which would depend on whether they were alive at
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Box: Models used for case mix adjustment
Unadjusted model
The simplest models, although accounting for the effect of clustering, used no additional covariate adjustment.
Adjusted model
A more complex model additionally controlled for residual imbalances in a set of characteristics predictive of future hospital use. These
characteristics included age, sex, ethnicity, site, number of chronic health conditions, principal long term condition (diabetes, chronic
obstructive pulmonary disease, or heart failure), an area based deprivation score (national quartiles of the index of multiple deprivation
2007), and a metric corresponding to the endpoint calculated over several periods within the two years before recruitment. The number of
chronic health conditions was a count of diagnoses recorded on inpatient data over the three years before starting the trial. We assigned
principal long term conditions using a pragmatic approach according to published criteria.13
Combined model
More complex case mix adjustment was conducted using the combined model.11 This model is a standard instrument designed to estimate
the probability that an individual would be admitted to an emergency hospital department within a 12 month period. The combined model
score accounts for 72 variables related to age, sex, recorded health conditions, previous hospital use, and prescriptions. These variables
are sourced using administrative data from general practices as well as from local hospital commissioning datasets.
The combined model was originally derived using data for 2002-05;11 we revalidated its performance on more recent data covering the period
from April 2007 to March 2009. Revalidation used data extracted for the trial sites excluding trial participants. For the case mix adjustment,
we calculated the combined model score for each participant at the end of the month before the start date. If a general practice did not grant
approval for us to extract data, we imputed scores for patients on the basis of the available information, which included age, sex, and hospital
data. We used single imputation on the basis of linear regression on the logit scale.
that point. Such effects may be different if telehealth affected
the mortality rate. Therefore, we did secondary analyses to
assess group differences in admission rates at any point in time,
on the condition that participants were alive just before that
point in time and had not already been admitted. This analysis
treated death as a form of statistical censoring and used the
Kaplan-Meier curve.23 Although the Kaplan-Meier curve did
not take into account differences between intervention and
control groups at baseline, we also estimated the corresponding
adjusted hazard ratio. We calculated hazard ratios using a Cox
proportional hazards model,24 which included covariate
adjustment according to the set of baseline variables (box) and
random frailties to allow for homogeneity within practices.25
Results
Data extraction, linkage, and processing
We allocated 238 practices to control or intervention groups.
Although 59 practices eventually did not supply participants
for the trial, sites assessed 15 171 patients for eligibility and
sent data sharing consent forms; 5279 (34.8%) of these patients
agreed to a “light touch” visit. Some patients did not consent
to take part in the trial after this visit. Sites recruited 1625
control patients and 1605 intervention patients from 179 general
practices (fig 1⇓), with each practice recruiting an average of
18 patients. Recruitment started in May 2008 and was planned
to finish in September 2009; we excluded seven patients who
were recruited after this finish date. In addition, 69 patients
could not be linked to administrative data on secondary care
use. Overall, we included 1584 control patients and 1570
intervention patients in the analyses (98% of those recruited).
We calculated full combined model scores for 1397 control and
1365 intervention patients (88% of those included in the
analyses), and imputed scores for the remainder of patients.
Most inpatient and outpatient hospital activity for the selected
patients could be assigned unit costs using our methods. We
assigned unit costs to 3189 (96.3%) of 3310 inpatient spells
experienced by participants during the 12 months before the
start of the trial, and to 13 670 (86.7%) of 15 766 outpatient
attendances.
Baseline characteristics and trends in hospitalactivity
Tables 1⇓ and 2⇓ show that intervention and control patients
were similar at baseline (all but one standardised difference
<10%). The largest difference between intervention and control
patients related to diabetes as an index condition (25.9% v
21.6%), followed by mean age (69.7 v 70.9 years). Intervention
patients also had less costly hospital activity than controls in
the 90 days before the start of the trial (£427 (€529; $662) v
£506).
Figure 2⇓ shows trends in hospital activity without adjusting
for clustering or baseline covariates (that is, as crude data). The
break in the chart corresponds to the trial start date, and the
chart summarises activity over a series of quarters before and
after this date. Rates of emergency hospital admission had
peaked for both intervention and control groups at around six
quarters before the start of the trial. After the trial began,
emergency admissions increased for the control group, from
0.13 per head in the quarter immediately before to 0.18 per head
in the quarter immediately after. Emergency department visits
also increased over this period, and the rate of conversion of
emergency department visits into admissions rose slightly from
53% to 58%. After the initial increase in activity for the control
group, rates of emergency admission for the two groups began
to converge, although a difference in favour of the intervention
group seemed to persist for the entire follow-up period. Table
3⇓ shows summary figures for the crude rates of hospital activity
during the follow-up period.
Analysis of primary and secondary endpoints
Of the intervention participants, 42.9%were admitted to hospital
during the 12 months of the trial, compared with 48.2% of
controls (table 3). These proportions corresponded to an
unadjusted odds ratio of 0.82 (95% confidence interval 0.70 to
0.97, P=0.017; table 4⇓). The odds ratio takes into account
clustering at the general practice level. The intracluster
correlation coefficient (0.017) was higher than assumed in the
original power calculations.
The odds ratio for the admission proportion at 12 months
remained significant after we adjusted for baseline characteristics
and also after we adjusted for the combined model score. We
assessed the performance of the combined model as a
discriminatory tool to predict emergency hospital admissions
by using data from the trial sites (excluding trial participants).
We estimated the area under the receiver operating
characteristics curve to be 0.746 (n=1 523 038).
During the trial, fewer participants died in the intervention group
than in the control group (4.6% v 8.3%; unadjusted odds ratio
0.54, 95% confidence interval 0.39 to 0.75, P<0.001).
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Differences remained significant after adjustment for the
combined model score, although we could not adjust for the set
of baseline characteristics because models did not converge.
Of the secondary endpoints, emergency admissions, emergency
department visits, bed days, and mortality showed significant
findings in some or all of the models. Intervention participants
underwent 0.54 emergency admissions per head, compared with
0.68 for controls (crude rates), corresponding to an unadjusted
incidence rate ratio of 0.81 (95% confidence interval 0.65 to
1.00, P=0.046). However, after we adjusted for baseline
characteristics, the upper end of the confidence interval for
emergency admissions reached 1.
On average, intervention participants attended emergency
departments 0.64 times per head during the trial, compared with
0.75 for controls. This difference was significant in the adjusted
estimates only (incidence rate ratio 0.85, 0.73 to 1.00, P=0.044).
The intervention and control groups spent an average of 4.87
and 5.68 days in hospital, respectively (unadjusted geometric
mean difference −0.64 days, −1.14 to −0.10, P=0.023); this
difference remained significant after adjustment.
Notional costs of hospital activity to commissioners of care
were £188 per head lower for intervention participants than for
controls (crude rates). Confidence intervals for the geometric
mean were very wide and differences were not significant in
any of the models (adjusted geometric mean difference −£242,
95% confidence interval −629 to 228, P=0.290).
Secondary analysis of the Kaplan-Meier curves and Cox
regression (fig 3⇓) confirmed that differences in the admission
proportion remained significant after censoring observations at
death (hazard ratio 0.87, 95% confidence interval 0.78 to 0.98,
implying fewer admissions for the telehealth than control group).
Graphical methods indicated that the underlying proportional
hazards assumption was reasonable.Where Schoenfeld residual
tests were significant,26 results remained robust to alternative
model specification.
Discussion
Principal findings of the study
Among a set of patients with chronic obstructive pulmonary
disease, diabetes, or heart failure, this study has shown that a
smaller proportion of telehealth users than controls were
admitted to hospital during a 12 month follow-up. This effect
remained significant after adjusting for baseline characteristics
and for a predictive risk score. However, the magnitude of the
group difference in admission proportion was relatively small
(10.8%, 95% confidence interval 3.7% to 18.1%), and smaller
than the size that the planned study design was able to detect
(17.5%), raising questions about the clinical relevance of the
results. The significance of some of the effects reflected the
increased power of the study, owing to the higher than assumed
baseline level of admissions and to the larger number of small
practices (even though the intracluster correlation coefficient
was higher than assumed).
Intervention patients were significantly less likely to die within
12 months than controls. We also observed small differences
in the mean number of emergency admissions per head between
the intervention and control groups (crude rate 0.54 v 0.68;
difference 0.14). These changes were significant in the
unadjusted comparisons and when we adjusted for a predictive
risk score, but not when we adjusted for baseline characteristics.
Hospital bed days were significantly lower among intervention
patients than controls, which reflected the reduced admission
proportion overall.
For the other measures of hospital use (including the number
of elective admissions, outpatient attendances, and emergency
department visits), group differences were not significant in
general. Crude differences in notional hospital costs to
commissioners of care were also not significant and were
relatively small (£188 per head over 12 months), especially
compared with the potentially high costs of these types of
telehealth intervention27-29, which we did not take into account.
In view of our results showing confidence intervals crossing
the line of no difference, we cannot conclude that telehealth
reduces secondary care costs over 12 months. A formal cost
effectiveness analysis of the Whole System Demonstrator
intervention has been undertaken on a subset of participants,
using self reported data for hospital use and other services and
taking into account the intervention cost, compared with health
related quality of life and other outcomes.
Differences in hospital use were at their most marked at the start
of the trial, when we observed a distinct increase in admissions
for the control group. If we excluded activity from the first three
months of the trial, differences in the admission proportion
would not have been significant under any of the models.
Therefore, this increase has implications for the interpretation.
Trial recruitment processes may have led indirectly to changes
in service use for control patients; however, the same processes
might also have affected intervention patients in the absence of
telehealth. In this case, differences in admissions can be
attributed to telehealth, but with the limitation that the trial could
have affected the context for the delivery of care for both trial
groups.
One explanation for the increase in emergency admissions
observed for the control group is that professionals may have
identified additional health problems and unmet needs during
the recruitment process and could have decided to intervene
with control patients not allocated to receive telehealth. This
explanation assumes that, if professionals found additional
relevant health problems among the intervention group, they
were content to manage these in a community setting, with the
support of the remote monitoring.
The trial recruitment process might have also raised patients’
awareness of their health conditions. Anxiety could have
increased as a result of being allocated to the control group, to
the extent that these patients were more likely to present at
emergency departments and be admitted than intervention
patients. The decision to offer telehealth to control patients at
the end of the 12 month period, while designed to reduce
attrition rates, could have increased anxiety if it encouraged a
stronger sense that they were being denied access to support
that could be beneficial. A final possible explanation for the
increase is that biases could have resulted during patient
selection, in which only 35% of patients agreed to the initial
“light touch” visit. There could have been a propensity to select
controls with a higher risk of short term admission and
intervention patients with a lower risk. However, observed
differences were limited between intervention and control
groups, and case mix adjustment was applied.
Strengths and weaknesses of the study
This particular analysis is one of a series planned by the Whole
System Demonstrator Evaluation Team, and was limited to
comparisons of inpatient, outpatient, and emergency department
hospital use and mortality. We did not consider the full range
of health and social care services, and intervention and control
groups could have had differences in the use of primary care,
community services, or social care. Telehealth could also have
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had different effects according to long term condition or other
patient characteristics. Although we assigned unit costs to more
than 95% of inpatient activity, we did not consider costs for
some elements of hospital care, including mental health and
critical care, which had no national tariff. Use of national tariffs
meant that the analysis was relevant to decisions made by
commissioners of care, who align with hospital reimbursement
guidance, but the economic costs of providing care will differ
from the notional costs shown here, and there are regional
differences in the costs of providing care.
Although service use could have resource implications, it does
not necessarily correlate with health status. Assessment of the
effect of interventions should be multidimensional,30 and
important differences could also exist in health outcomes, cost
effectiveness, and patient perceptions. These outcomes are
explored in the related theme analyses. Telehealth could also
have had knock-on effects in non-study patient groups, by
freeing up clinical time and resources to care for non-study
patients, or by diverting the attention of community teams
towards those patients on the trial.
The study used administrative datasets. As a result, person level
data were available for 98% of participants. Although these
datasets avoided problems of non-response, the quality of data
was not directly under the research team’s control. Patients tend
to underestimate resource use compared with healthcare
providers,31 but several studies have pointed out potential
problems with using administrative data, such as limited insight
into the quality and appropriateness of care.32 33
Selection bias is recognised as a risk in cluster randomised trials,
in which systematic differences can occur between intervention
and control groups at both the cluster and individual level.19 At
the individual level, if the trial recruiters had foreknowledge of
the allocation group (as was often the case here), bias can result
through the recruitment of different types of participant into the
two groups. We designed this trial to minimise the possibility
of bias within the context of a complex community based
intervention. An independent team randomised allocations of
practices and a minimisation algorithm aimed to ensure that
intervention and control practices were similar in terms of
practice size, disease prevalence, and other characteristics. At
the individual level, we found no large differences in the
characteristics of control and intervention participants at
baseline. However, we saw group differences in the median
number of participants per general practice (8.5 for telehealth
v 12 for controls). Case mix adjustment controlled for observed
differences between intervention and control groups.
We based this analysis on an intention to treat method, which
compares patients according to their assigned intervention or
control group. Although some patients did not receive their
allocated interventions, these numbers were small. A substantial
proportion of the intervention group could have stopped using
telehealth before the end of the 12 months. This study had
conservative estimates because, in other telehealth applications,
equipment might be removed from patients who stop using it.34
The trial design aimed to minimise differential rates of attrition
between intervention and control groups, by ensuring that all
practices were allocated to receive a telemonitoring intervention
(telehealth or telecare), and that control participants were offered
a telemonitoring intervention at the end of the trial period, if
they were still eligible.
The effect of telehealth should be considered as just one element
within the health system in which it was used. All participating
practices and patients in the study could have benefited from
the wider service redesign associated with these trials, including
those assigned to usual care. Therefore, the study assessed the
added value of telehealth over and above the effects of this wider
service redesign.
The study aimed to review a broad class of telehealth devices
and not to compare specific devices and monitoring systems.
Our results reflect specific models of the introduction of
telehealth, based on a series of decisions by local teams. There
were differences in the interventions offered by the three sites.
Although this plurality might be seen as problematic for the
purposes of replicating and linking specific aspects of the
interventions to likely changes in hospital use, in some ways it
is the merit of a pragmatic trial. Other sites introducing
telehealth will make choices driven by local contexts in the
same way as did the sites in the present study, so the ability to
reflect real life applications of telehealth will add generalisability
to the study findings. However, the sites were specifically
chosen for their innovations in these areas of care, and
conclusions about the effectiveness of telehealth might depend
on the environment in which it is used.
Strengths andweaknesses in relation to otherstudies
Assessment of the effectiveness of telehealth is usually based
on assimilating evidence from several small trials, which could
make findings difficult to generalise. By contrast, with over
3100 participants, this study is one of the largest randomised
trials of telehealth done so far. The focus on combining three
disease groups is novel and allowed us to examine the overall
effect of telehealth across populations with chronic disease.
However, telehealth could have varying effects in different
groups. Other studies have typically examined condition groups
separately; thus, comparisons between studies are not
straightforward.
Paré and colleagues reviewed 65 empirical studies across four
conditions and distinguished the effects of telehealth between
different conditions. They suggested that effects on a range of
measures (for example, reduced visits to emergency
departments, hospital admissions, and average length of hospital
stay) were more consistent in pulmonary and cardiac disorders
than in diabetes and hypertension.35
A systematic review of studies for heart failure reported that
telemonitoring reduced all cause mortality, whereas both
telemonitoring and structured telephone support reduced
admissions for heart failure.36However, findings were based on
generalising a large number of studies with a mean sample size
of 330. A study showed that a telehealth intervention that
included portable devices significantly reduced costs and
admissions for people with heart failure. This was based on a
sample size of 460, although the study was adequately powered
for the larger effect size it assumed.29 A more recent study of
1653 patients with heart failure found no significant effect on
hospital use or mortality.37 In relation to the management of
chronic obstructive pulmonary disease, several studies showed
lower rates of emergency admissions for patients receiving home
monitoring plus telephone support,38-40 although one review
noted that mortality rates were greater in patients receiving
telephone support than those receiving usual care.39 Evaluations
of telehealth interventions for people with diabetes have focused
on the achievement of a clinical outcome in terms of glycaemic
control,41 42 with some reported success.
There is also a question about the effect of interventions that
combine telemonitoring with educational andmotivational tools,
such as those we studied, comparedwith interventions consisting
of telemonitoring only. Our study was not designed to answer
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this question. In a study by Domingo and colleagues of patients
with heart failure receiving multidisciplinary care, those who
used motivational support tools combined with telemonitoring
of weight, blood pressure, and heart rate, thought that their
quality of life had improved. These patients also spent less time
in hospital after the intervention than before, although before
and after comparisons can be vulnerable to regression to the
mean. Researchers randomised patients to groups with and
without the telemonitoring element and found no significant
group differences.43
Possible explanations and implications forclinicians and policymakers and otherresearchers
Our results suggest that telehealth helped patients to avoid the
need for emergency hospital care. The mechanism for this is
not yet clear. Telehealth could help patients manage their
conditions better and therefore reduce the incidence of acute
exacerbations that need emergency admissions. Telehealth could
also change people’s perception of when they need to seek
additional support, as well as professionals’ decisions about
whether to refer or admit patients. Further analyses will provide
insights into the mechanisms by which telehealth can lead to
reductions in admission rates.13
The reduced mortality observed in the intervention group will
be an important motivator to invest in these interventions and
similar technologies. Although the observed difference in
emergency admissions associated with the intervention indicates
some potential to reduce use of secondary care, the findings
need to be tempered by the estimated scale of the difference in
notional hospital cost savings for commissioners of care and
the cost of the intervention. Furthermore, the increases seen in
emergency admissions among control participants suggest that
the trial recruitment processes had an impact. The effect on
quality of life must also be considered as part of a broader cost
effectiveness analysis. For commissioners of care services, there
are questions about whether any reduction in hospital use for
patients receiving telehealth translates to an overall change at
the organisational level. Any bed days released as a result could
be filled with non-study patients rather than released as cash
savings. In turn, this could have meant that health benefits
accrued to non-study patients, which were not taken into account
here.
The observation of a group effect between intervention and
controls could mask differences by subgroups. For local
practitioners, it is important to assess whether benefits of
telehealth are greater in particular patient types, to inform
decisions about prioritising the intervention in specific patient
groups. For example, Maclean and colleagues observed that
telehealth interventions probably did not result in clinically
relevant improvements in health outcomes in patients with
relatively mild asthma,44 but could have a role in patients with
more severe disease who are at high risk of admission. The
current study was not designed to answer these specific
questions.
The effect of telehealth could be intricately linked to wider
issues about how health systems operate. It is unclear whether
effects are attributable to the technology itself or attributable to
how it is implemented,34 and telehealth could be disruptive
because it requires some professional groups to work in different
ways.
This analysis is one part of the complete evaluation, and the
Whole System Demonstrator trial in its entirety will allow a
wider discussion of issues around the effects on cost
effectiveness, quality of life, and patients’ and carers’
experiences as well as changes at the organisational level.
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Tables
Table 1| Baseline characteristics of study patients. Data are no (%) of patients unless stated otherwise
Standardised difference (%)Intervention group (n=1570)Control group (n=1584)
—9285No of practices
—8 (1-77)12 (1-98)No of patients per practice (median (range))
Index long term condition
−5.1739 (47.1)786 (49.6)Chronic obstructive pulmonary disease
10.0406 (25.9)342 (21.6)Diabetes
−3.8425 (27.1)456 (28.8)Heart failure
−3.01.8 (1.8)1.8 (1.8)No of chronic health conditions per patient
(mean (SD))
Site
−6.7558 (35.5)614 (38.8)Cornwall
−1.0563 (35.9)576 (36.4)Kent
8.4449 (28.6)394 (24.9)Newham
Age
−9.769.7 (11.6)70.9 (11.7)Mean (SD) age in years
2.9463 (29.5)446 (28.2)<65 years
7.1548 (34.9)500 (31.6)65-74 years
−6.9446 (28.4)500 (31.6)75-84 years
−5.6113 (7.2)138 (8.7)≥85 years
1.3647 (41.2)643 (40.6)Female
Ethnicity
−4.41127 (71.8)1168 (73.7)White
2.1182 (11.6)173 (10.9)Non-white
3.5261 (16.6)243 (15.3)Unknown
Area level deprivation*
2.928.4 (14.8)27.9 (13.5)Mean (SD)
8.0137 (8.8)105 (6.6)First quartile
−1.8258 (16.5)272 (17.2)Second quartile
−5.6522 (33.4)571 (36.1)Third quartile
2.5644 (41.3)633 (40.0)Fourth quartile
Combined model score†
−0.30.260 (0.202)0.261 (0.200)Mean (SD)
0.0221 (16.2)226 (16.2)Low risk category
3.0440 (32.2)431 (30.9)Moderate risk category
−2.7559 (41.0)591 (42.3)High risk category
−0.1145 (10.6)149 (10.7)Very high risk category
SD=standard deviation.
*N=1581 for control group, n=1561 for intervention group. First quartile is least deprived, fourth quartile is most deprived.
†N=1397 for control group, n=1365 for intervention group. Risk categories denote top proportions of site population: very high risk (0.5%), high risk (0.5-5%),
moderate risk (5-20%), and low risk (20-100%).
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Table 2| Baseline characteristics of study patients, in relation to previous hospital use before start of trial. Data aremean (standard deviation)
unless stated otherwise
Standardised difference (%)Intervention group (n=1570)Control group (n=1584)Characteristic and period before start of trial
Admission proportion (%)
−3.216.3 (n=256)17.5 (n=277)1-90 days
0.139.3 (n=617)39.3 (n=622)91-365 days
−4.947.1 (n=740)49.6 (n=785)366-730 days
Emergency admissions per head
−3.30.11 (0.44)0.13 (0.45)1-90 days
−3.80.42 (0.94)0.45 (1.01)91-365 days
−5.50.54 (1.07)0.60 (1.19)366-730 days
Bed days per head
−2.30.84 (3.81)0.94 (4.69)1-90 days
−5.33.00 (8.96)3.54 (11.25)91-365 days
−0.64.57 (12.77)4.65 (11.45)366-730 days
Elective admissions per head
0.50.11 (0.48)0.11 (0.40)1-90 days
0.60.36 (1.10)0.36 (0.95)91-365 days
−2.30.49 (1.30)0.52 (1.29)366-730 days
Outpatient attendances per head
−4.71.14 (1.97)1.23 (1.97)1-90 days
−2.43.75 (4.98)3.87 (5.24)91-365 days
−1.94.63 (6.12)4.75 (6.35)366-730 days
Emergency department visits per head
1.10.14 (0.48)0.13 (0.44)1-90 days
0.90.42 (1.10)0.41 (1.05)91-365 days
−1.10.46 (1.21)0.47 (1.05)366-730 days
Tariff cost per head (£ per head)
−6.3427 (1177)506 (1311)1-90 days
−5.11706 (3116)1879 (3712)91-365 days
−2.72296 (4143)2411 (4342)366-730 days
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Table 3| Hospital use andmortality during trial (unadjusted for clustering and covariates). Data are mean (standard deviation) unless stated
otherwise
Percentage difference (95% CI)Absolute difference (95% CI)Intervention group (n=1570)Control group (n=1584)
−10.8% (−18.1% to −3.7%)−5.2 (−8.7 to −1.8)42.9 (n=674)48.2 (n=763)Admission proportion (%)
−44.5% (−65.3% to −23.8%)−3.7 (−5.4 to −2.0)4.6 (n=72)8.3 (n=131)Mortality (%)
−20.6% (−33.8% to −7.4%)−0.14 (−0.23 to −0.05)0.54 (1.16)0.68 (1.41)Emergency admissions per head
−14.3% (−30.6% to 2.0%)−0.07 (−0.15 to 0.01)0.42 (0.99)0.49 (1.31)Elective admissions per head
1.7% (−8.3% to 11.8%)0.08 (−0.39 to 0.55)4.76 (6.74)4.68 (6.81)Outpatient attendances per head
−14.7% (−28.0% to −1.3%)−0.11 (−0.21 to −0.01)0.64 (1.26)0.75 (1.58)Emergency department visits per
head
−14.3% (−32.4% to 3.9%)−0.81 (−1.84 to 0.22)4.87 (14.35)5.68 (15.10)Bed days per head
−7.7% (−19.4% to 4.0%)188 (−474.9 to 98.8)2260 (4117)2448 (4099)Tariff costs per head (£)
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Table 4| Results of mixed models (including case mix adjustment)
PEstimate (95% CI)ModelEndpoint (interpretation)
0.0170.82 (0.70 to 0.97)UnadjustedAdmission proportion (odds ratio)
0.0260.82 (0.69 to 0.98)Adjusted
0.0160.82 (0.69 to 0.96)Combined model
<0.0010.54 (0.39 to 0.75)UnadjustedMortality (odds ratio)*
<0.0010.53 (0.39 to 0.72)Combined model
0.0460.81 (0.65 to 1.00)UnadjustedEmergency admissions (incidence rate ratio)
0.0560.85 (0.72 to 1.00)Adjusted
0.0110.81 (0.69 to 0.95)Combined model
0.2190.89 (0.75 to 1.07)UnadjustedElective admissions (incidence rate ratio)
0.0780.87 (0.74 to 1.02)Adjusted
0.2410.90 (0.76 to 1.07)Combined model
0.6210.96 (0.81 to 1.13)UnadjustedOutpatient attendances (incidence rate ratio)
0.8141.01 (0.92 to 1.12)Adjusted
0.5750.95 (0.81 to 1.13)Combined model
0.1350.85 (0.70 to 1.05)UnadjustedEmergency department visits (incidence rate ratio)
0.0440.85 (0.73 to 1.00)Adjusted
0.0910.86 (0.72 to 1.02)Combined model
0.023−0.64 (−1.14 to −0.10)UnadjustedBed days (difference in geometric means)
0.047−0.44 (−0.85 to −0.01)Adjusted
0.013−0.58 (−1.00 to −0.13)Combined model
0.181−449 (−964 to 243)UnadjustedTariff costs (difference in geometric means (£))
0.290−242 (−629 to 228)Adjusted
0.184−382 (−840 to 206)Combined model
*One of the models did not converge for mortality.
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Figures
Fig 1 CONSORT diagram
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Fig 2 Crude trends in secondary care activity for patients recruited into the study
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Fig 3 Kaplan-Meier survival analysis for admission proportion
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